Virbac has launched Prinovox, a new prescription-only spot-on ectoparasiticide, containing the industry-leading combination of Moxidectin and Imidacloprid. It is presented with a unique and highly innovative pet owner engagement programme to help practices to build loyalty, increase compliance and to encourage repeat purchase.
Prinovox contains the same combination of Moxidectin and Imidacloprid as the market leader, offering a wide spectrum of activity against parasites. In dogs it is licensed for the treatment and prevention of lungworm; for the treatment and prevention of fleas and also for lice, mites, heartworm and roundworms. In cats, the licence covers fleas, mites, roundworm and heart worm. It can also be used for fleas and heartworm in ferrets.
Offered in six presentations to suit all weight ranges and in packs of four pipettes, Prinovox features bright, interactive packaging using the Blippar platform which Virbac successfully introduced with its new wormer, Milpro. By downloading the free Blippar app onto a device, owners can ‘blip’ interactive icons on the product’s packaging to gain access to additional information on Prinovox, including a video on how to use it, a reminder system and a fun game.
Other elements of the Prinovox support package include:
- A Client Prinovox Kit to be given to clients on purchase, which includes educational information, competitions and collectable items
- Two suites of in-practice display materials, including posters, character-based leaflet dispensers and collectables to encourage family involvement
- A Kids Club which invites children to become members of the’ Creepy Crawley Intelligence Agency’ (CCIA). Members receive four activity packs a year in addition to competitions and collectable items.
Commenting on the launch of Prinovox, Head of Marketing (Companion Animal Simon Boulton MRCVS, said: “We see the launch of Prinovox as a gamechanger. The ectoparasiticide market is one of the largest and most competitive in our industry and we are the first company to offer a product with the same efficacy as the market leader for all indications.
“We’ve gone one step further by increasing the value of the product to practices by developing a comprehensive parasite protection support package which harnesses the latest technology and consumer preferences for receiving information. We believe the efficacy of Prinovox, combined with the innovative support package we’re offering, will make it a highly attractive product for practices and owners and we’ve been delighted at the feedback we’ve received so far.”
The addition of Prinovox and the recently introduced wormer Milpro means that Virbac now offers both an oral or spot-on solution for the treatment and prevention of lungworm. Its other parasiticide products include its Effipro spot-on, its market-leading environmental flea treatment Indorex and the wormer, Endogard.
Founded by a veterinary surgeon, Virbac is dedicated to supporting the veterinary profession, the trade and farmers through the development of innovative products and services, which help animals to lead longer, healthier lives. One of the largest independent veterinary pharmaceutical companies in the world, its wide product portfolio includes many market-leading and award-winning products for large and small animals.
Virbac aims to work in close partnership with its customers, providing the advice and support they need to run successful, profitable